Literature DB >> 19009014

Chronic lymphocytic leukemia cells recognize conserved epitopes associated with apoptosis and oxidation.

Rosa Catera1, Gregg J Silverman, Katerina Hatzi, Till Seiler, Sebastien Didier, Lu Zhang, Maxime Hervé, Eric Meffre, David G Oscier, Helen Vlassara, R Hal Scofield, Yifang Chen, Steven L Allen, Jonathan Kolitz, Kanti R Rai, Charles C Chu, Nicholas Chiorazzi.   

Abstract

Chronic lymphocytic leukemia (CLL) represents the outgrowth of a CD5(+) B cell. Its etiology is unknown. The structure of membrane Ig on CLL cells of unrelated patients can be remarkably similar. Therefore, antigen binding and stimulation could contribute to clonal selection and expansion as well as disease promotion. Initial studies suggest that CLL mAbs bind autoantigens. Since apoptosis can make autoantigens accessible for recognition by antibodies, and also create neo-epitopes by chemical modifications occurring naturally during this process, we sought to determine if CLL mAbs recognize autoantigens associated with apoptosis. In general, ~60% of CLL mAbs bound the surfaces of apoptotic cells, were polyreactive, and expressed unmutated IGHV. mAbs recognized two types of antigens: native molecules located within healthy cells, which relocated to the external cell surface during apoptosis; and/or neoantigens, generated by oxidation during the apoptotic process. Some of the latter epitopes are similar to those on bacteria and other microbes. Although most of the reactive mAbs were not mutated, the use of unmutated IGHV did not bestow autoreactivity automatically, since several such mAbs were not reactive. Particular IGHV and IGHV/D/J rearrangements contributed to autoantigen binding, although the presence and degree of reactivity varied based on specific structural elements. Thus, clonal expansion in CLL may be stimulated by autoantigens occurring naturally during apoptosis. These data suggest that CLL may derive from normal B cells whose function is to remove cellular debris, and also to provide a first line of defense against pathogens.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19009014      PMCID: PMC2582860          DOI: 10.2119/2008-00102.Catera

Source DB:  PubMed          Journal:  Mol Med        ISSN: 1076-1551            Impact factor:   6.354


  53 in total

1.  Subsets with restricted immunoglobulin gene rearrangement features indicate a role for antigen selection in the development of chronic lymphocytic leukemia.

Authors:  Gerard Tobin; Ulf Thunberg; Karin Karlsson; Fiona Murray; Anna Laurell; Kerstin Willander; Gunilla Enblad; Mats Merup; Juhani Vilpo; Gunnar Juliusson; Christer Sundström; Ola Söderberg; Göran Roos; Richard Rosenquist
Journal:  Blood       Date:  2004-06-24       Impact factor: 22.113

2.  All T15 Id-positive antibodies (but not the majority of VHT15+ antibodies) are produced by peritoneal CD5+ B lymphocytes.

Authors:  H Masmoudi; T Mota-Santos; F Huetz; A Coutinho; P A Cazenave
Journal:  Int Immunol       Date:  1990       Impact factor: 4.823

3.  The role of clonal selection and somatic mutation in autoimmunity.

Authors:  M J Shlomchik; A Marshak-Rothstein; C B Wolfowicz; T L Rothstein; M G Weigert
Journal:  Nature       Date:  1987 Aug 27-Sep 2       Impact factor: 49.962

4.  Naturally occurring antibodies against nine common antigens in human sera. I. Detection, isolation and characterization.

Authors:  B Guilbert; G Dighiero; S Avrameas
Journal:  J Immunol       Date:  1982-06       Impact factor: 5.422

5.  Chronic lymphocytic leukemic (CLL) cells secrete multispecific autoantibodies.

Authors:  B M Bröker; A Klajman; P Youinou; J Jouquan; C P Worman; J Murphy; L Mackenzie; R Quartey-Papafio; M Blaschek; P Collins
Journal:  J Autoimmun       Date:  1988-10       Impact factor: 7.094

6.  Chronic lymphocytic leukemia antibodies with a common stereotypic rearrangement recognize nonmuscle myosin heavy chain IIA.

Authors:  Charles C Chu; Rosa Catera; Katerina Hatzi; Xiao-Jie Yan; Lu Zhang; Xiao Bo Wang; Henry M Fales; Steven L Allen; Jonathan E Kolitz; Kanti R Rai; Nicholas Chiorazzi
Journal:  Blood       Date:  2008-09-23       Impact factor: 22.113

7.  Antiphosphocholine antibodies found in normal mouse serum are protective against intravenous infection with type 3 streptococcus pneumoniae.

Authors:  D E Briles; M Nahm; K Schroer; J Davie; P Baker; J Kearney; R Barletta
Journal:  J Exp Med       Date:  1981-03-01       Impact factor: 14.307

8.  Evidence that chronic lymphocytic leukemia B lymphocytes are frequently committed to production of natural autoantibodies.

Authors:  L Borche; A Lim; J L Binet; G Dighiero
Journal:  Blood       Date:  1990-08-01       Impact factor: 22.113

9.  Production of autoantibodies by CD5-expressing B lymphocytes from patients with chronic lymphocytic leukemia.

Authors:  Z M Sthoeger; M Wakai; D B Tse; V P Vinciguerra; S L Allen; D R Budman; S M Lichtman; P Schulman; L R Weiselberg; N Chiorazzi
Journal:  J Exp Med       Date:  1989-01-01       Impact factor: 14.307

10.  Multiple distinct sets of stereotyped antigen receptors indicate a role for antigen in promoting chronic lymphocytic leukemia.

Authors:  Bradley T Messmer; Emilia Albesiano; Dimitar G Efremov; Fabio Ghiotto; Steven L Allen; Jonathan Kolitz; Robin Foa; Rajendra N Damle; Franco Fais; Davorka Messmer; Kanti R Rai; Manlio Ferrarini; Nicholas Chiorazzi
Journal:  J Exp Med       Date:  2004-08-16       Impact factor: 14.307

View more
  91 in total

1.  Enhanced outgrowth of EBV-transformed chronic lymphocytic leukemia B cells mediated by coculture with macrophage feeder cells.

Authors:  Kwan-Ki Hwang; Xi Chen; Daniel M Kozink; Marietta Gustilo; Dawn J Marshall; John F Whitesides; Hua-Xin Liao; Rosa Catera; Charles C Chu; Xiao-Jie Yan; Micah A Luftig; Barton F Haynes; Nicholas Chiorazzi
Journal:  Blood       Date:  2011-12-12       Impact factor: 22.113

2.  High-density screening reveals a different spectrum of genomic aberrations in chronic lymphocytic leukemia patients with 'stereotyped' IGHV3-21 and IGHV4-34 B-cell receptors.

Authors:  Millaray Marincevic; Nicola Cahill; Rebeqa Gunnarsson; Anders Isaksson; Mahmoud Mansouri; Hanna Göransson; Markus Rasmussen; Mattias Jansson; Fergus Ryan; Karin Karlsson; Hans-Olov Adami; Fred Davi; Jesper Jurlander; Gunnar Juliusson; Kostas Stamatopoulos; Richard Rosenquist
Journal:  Haematologica       Date:  2010-04-26       Impact factor: 9.941

Review 3.  Cellular origin(s) of chronic lymphocytic leukemia: cautionary notes and additional considerations and possibilities.

Authors:  Nicholas Chiorazzi; Manlio Ferrarini
Journal:  Blood       Date:  2010-12-09       Impact factor: 22.113

4.  Biological and clinical significance of stereotyped B-cell receptors in chronic lymphocytic leukemia.

Authors:  Davide Rossi; Gianluca Gaidano
Journal:  Haematologica       Date:  2010-12       Impact factor: 9.941

5.  Identification of a novel stereotypic IGHV4-59/IGHJ5-encoded B-cell receptor subset expressed by various B-cell lymphomas with high affinity rheumatoid factor activity.

Authors:  Richard J Bende; Jerry Janssen; Thera A M Wormhoudt; Koen Wagner; Jeroen E J Guikema; Carel J M van Noesel
Journal:  Haematologica       Date:  2016-02-08       Impact factor: 9.941

Review 6.  Targeting the B cell receptor pathway in non-Hodgkin lymphoma.

Authors:  Kelly Valla; Christopher R Flowers; Jean L Koff
Journal:  Expert Opin Investig Drugs       Date:  2018-06-07       Impact factor: 6.206

7.  Excessive antigen reactivity may underlie the clinical aggressiveness of chronic lymphocytic leukemia stereotyped subset #8.

Authors:  Maria Gounari; Stavroula Ntoufa; Benedetta Apollonio; Nikos Papakonstantinou; Maurilio Ponzoni; Charles C Chu; Davide Rossi; Gianluca Gaidano; Nicholas Chiorazzi; Kostas Stamatopoulos; Paolo Ghia
Journal:  Blood       Date:  2015-04-21       Impact factor: 22.113

8.  Regulation of dendritic cells and macrophages by an anti-apoptotic cell natural antibody that suppresses TLR responses and inhibits inflammatory arthritis.

Authors:  Yifang Chen; Sahil Khanna; Carl S Goodyear; Yong Beom Park; Eyal Raz; Steffen Thiel; Caroline Grönwall; Jaya Vas; David L Boyle; Maripat Corr; Dwight H Kono; Gregg J Silverman
Journal:  J Immunol       Date:  2009-06-29       Impact factor: 5.422

9.  An entity evolving into a community: defining the common ancestor and evolutionary trajectory of chronic lymphocytic leukemia stereotyped subset #4.

Authors:  Lesley-Ann Sutton; Giorgos Papadopoulos; Anastasia Hadzidimitriou; Stavros Papadopoulos; Efterpi Kostareli; Richard Rosenquist; Dimitrios Tzovaras; Kostas Stamatopoulos
Journal:  Mol Med       Date:  2015-04-02       Impact factor: 6.354

Review 10.  From pathogenesis to treatment of chronic lymphocytic leukaemia.

Authors:  Thorsten Zenz; Daniel Mertens; Ralf Küppers; Hartmut Döhner; Stephan Stilgenbauer
Journal:  Nat Rev Cancer       Date:  2009-12-03       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.